Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Maintains $1152 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst John Newman maintains a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target of $1152.
June 27, 2024 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst John Newman maintains a Buy rating on Regeneron Pharmaceuticals with a price target of $1152.
The reaffirmation of a Buy rating and a high price target of $1152 by a reputable analyst is likely to positively influence investor sentiment and drive short-term price appreciation for Regeneron Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100